Alpha-synuclein in cerebrospinal fluid

Takahiko Tokuda, Ryotaro Ishii, Harutsugu Tatebe, Takashi Kasai, Omar Ali El-Agnaf

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The current status of biochemical biomarker candidates for dementia with Lewy bodies (DLB) and synucleinopathy has been previously discussed. The majority of the studies on biochemical biomarkers were cross-sectional, retrospective, and tested with pathologically unproven subjects. α-Synuclein (A-syn) plays a pivotal role both in the development of the disease and propagation of the pathology in Parkinson’s disease (PD). Levels of total A-syn in cerebrospinal fluid (CSF) can discriminate PD from controls or tauopathies as groups. However, it is hard to diagnose an individual patient according to the level of CSF A-syn alone. The CSF total A-syn could also be useful as a surrogate biomarker for PD for monitoring the severity of the disease. CSF levels of A-syn oligomers could be a promising biomarker for the diagnosis of PD and are reported to correlate with motor and cognitive scores in PD, also suggesting their possible ability as a biomarker to monitor disease severity. With regard to the diagnosis of DLB, some studies, including two meta-analyses, demonstrated significantly lower CSF levels of total A-syn in DLB patients compared to AD patients. However, the sensitivity and specificity as well as diagnostic ability of CSF total A-syn remain to be elucidated. Whether CSF A-syn oligomers are useful or not for the diagnosis of DLB has not been examined. To study plasma levels of total and oligomeric A-syn, it is essential to eliminate the interference from heterophilic antibodies that have a significant impact on the assays of plasma A-syn, despite never being considered in any of the studies reported so far. For future studies developing biochemical biomarkers for DLB and synucleinopathy, it will be necessary to not only validate the already reported candidates and translate them to clinical practice but also to identify novel biomarkers that are more closely associated with the underlying pathophysiologies, including certain oligomers or protofibrils of A-syn that are specifically relevant to neurotoxicity and/or prion-like propagation of the diseases. To accomplish these goals, a large, prospective, and longitudinal cohort study carried out using standardized diagnostic criteria and stringent protocols with quality-controlled methods will definitely be needed.

Original languageEnglish
Title of host publicationDementia with Lewy Bodies: Clinical and Biological Aspects
PublisherSpringer Japan
Pages171-192
Number of pages22
ISBN (Electronic)9784431559481
ISBN (Print)9784431559467
DOIs
Publication statusPublished - 1 Jan 2016
Externally publishedYes

Fingerprint

alpha-Synuclein
Lewy Body Disease
Cerebrospinal Fluid
Biomarkers
Parkinson Disease
Aptitude
Synucleins
Tauopathies
Prions
Longitudinal Studies
Meta-Analysis
Cohort Studies
Pathology
Sensitivity and Specificity
Antibodies

Keywords

  • Biochemical biomarker
  • Cerebrospinal fluid
  • Dementia with Lewy bodies
  • Oligomer
  • α-Synuclein

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tokuda, T., Ishii, R., Tatebe, H., Kasai, T., & Ali El-Agnaf, O. (2016). Alpha-synuclein in cerebrospinal fluid. In Dementia with Lewy Bodies: Clinical and Biological Aspects (pp. 171-192). Springer Japan. https://doi.org/10.1007/978-4-431-55948-1_13

Alpha-synuclein in cerebrospinal fluid. / Tokuda, Takahiko; Ishii, Ryotaro; Tatebe, Harutsugu; Kasai, Takashi; Ali El-Agnaf, Omar.

Dementia with Lewy Bodies: Clinical and Biological Aspects. Springer Japan, 2016. p. 171-192.

Research output: Chapter in Book/Report/Conference proceedingChapter

Tokuda, T, Ishii, R, Tatebe, H, Kasai, T & Ali El-Agnaf, O 2016, Alpha-synuclein in cerebrospinal fluid. in Dementia with Lewy Bodies: Clinical and Biological Aspects. Springer Japan, pp. 171-192. https://doi.org/10.1007/978-4-431-55948-1_13
Tokuda T, Ishii R, Tatebe H, Kasai T, Ali El-Agnaf O. Alpha-synuclein in cerebrospinal fluid. In Dementia with Lewy Bodies: Clinical and Biological Aspects. Springer Japan. 2016. p. 171-192 https://doi.org/10.1007/978-4-431-55948-1_13
Tokuda, Takahiko ; Ishii, Ryotaro ; Tatebe, Harutsugu ; Kasai, Takashi ; Ali El-Agnaf, Omar. / Alpha-synuclein in cerebrospinal fluid. Dementia with Lewy Bodies: Clinical and Biological Aspects. Springer Japan, 2016. pp. 171-192
@inbook{d7d8676a778c44f2b6735a848fbabbcb,
title = "Alpha-synuclein in cerebrospinal fluid",
abstract = "The current status of biochemical biomarker candidates for dementia with Lewy bodies (DLB) and synucleinopathy has been previously discussed. The majority of the studies on biochemical biomarkers were cross-sectional, retrospective, and tested with pathologically unproven subjects. α-Synuclein (A-syn) plays a pivotal role both in the development of the disease and propagation of the pathology in Parkinson’s disease (PD). Levels of total A-syn in cerebrospinal fluid (CSF) can discriminate PD from controls or tauopathies as groups. However, it is hard to diagnose an individual patient according to the level of CSF A-syn alone. The CSF total A-syn could also be useful as a surrogate biomarker for PD for monitoring the severity of the disease. CSF levels of A-syn oligomers could be a promising biomarker for the diagnosis of PD and are reported to correlate with motor and cognitive scores in PD, also suggesting their possible ability as a biomarker to monitor disease severity. With regard to the diagnosis of DLB, some studies, including two meta-analyses, demonstrated significantly lower CSF levels of total A-syn in DLB patients compared to AD patients. However, the sensitivity and specificity as well as diagnostic ability of CSF total A-syn remain to be elucidated. Whether CSF A-syn oligomers are useful or not for the diagnosis of DLB has not been examined. To study plasma levels of total and oligomeric A-syn, it is essential to eliminate the interference from heterophilic antibodies that have a significant impact on the assays of plasma A-syn, despite never being considered in any of the studies reported so far. For future studies developing biochemical biomarkers for DLB and synucleinopathy, it will be necessary to not only validate the already reported candidates and translate them to clinical practice but also to identify novel biomarkers that are more closely associated with the underlying pathophysiologies, including certain oligomers or protofibrils of A-syn that are specifically relevant to neurotoxicity and/or prion-like propagation of the diseases. To accomplish these goals, a large, prospective, and longitudinal cohort study carried out using standardized diagnostic criteria and stringent protocols with quality-controlled methods will definitely be needed.",
keywords = "Biochemical biomarker, Cerebrospinal fluid, Dementia with Lewy bodies, Oligomer, α-Synuclein",
author = "Takahiko Tokuda and Ryotaro Ishii and Harutsugu Tatebe and Takashi Kasai and {Ali El-Agnaf}, Omar",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-4-431-55948-1_13",
language = "English",
isbn = "9784431559467",
pages = "171--192",
booktitle = "Dementia with Lewy Bodies: Clinical and Biological Aspects",
publisher = "Springer Japan",
address = "Japan",

}

TY - CHAP

T1 - Alpha-synuclein in cerebrospinal fluid

AU - Tokuda, Takahiko

AU - Ishii, Ryotaro

AU - Tatebe, Harutsugu

AU - Kasai, Takashi

AU - Ali El-Agnaf, Omar

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The current status of biochemical biomarker candidates for dementia with Lewy bodies (DLB) and synucleinopathy has been previously discussed. The majority of the studies on biochemical biomarkers were cross-sectional, retrospective, and tested with pathologically unproven subjects. α-Synuclein (A-syn) plays a pivotal role both in the development of the disease and propagation of the pathology in Parkinson’s disease (PD). Levels of total A-syn in cerebrospinal fluid (CSF) can discriminate PD from controls or tauopathies as groups. However, it is hard to diagnose an individual patient according to the level of CSF A-syn alone. The CSF total A-syn could also be useful as a surrogate biomarker for PD for monitoring the severity of the disease. CSF levels of A-syn oligomers could be a promising biomarker for the diagnosis of PD and are reported to correlate with motor and cognitive scores in PD, also suggesting their possible ability as a biomarker to monitor disease severity. With regard to the diagnosis of DLB, some studies, including two meta-analyses, demonstrated significantly lower CSF levels of total A-syn in DLB patients compared to AD patients. However, the sensitivity and specificity as well as diagnostic ability of CSF total A-syn remain to be elucidated. Whether CSF A-syn oligomers are useful or not for the diagnosis of DLB has not been examined. To study plasma levels of total and oligomeric A-syn, it is essential to eliminate the interference from heterophilic antibodies that have a significant impact on the assays of plasma A-syn, despite never being considered in any of the studies reported so far. For future studies developing biochemical biomarkers for DLB and synucleinopathy, it will be necessary to not only validate the already reported candidates and translate them to clinical practice but also to identify novel biomarkers that are more closely associated with the underlying pathophysiologies, including certain oligomers or protofibrils of A-syn that are specifically relevant to neurotoxicity and/or prion-like propagation of the diseases. To accomplish these goals, a large, prospective, and longitudinal cohort study carried out using standardized diagnostic criteria and stringent protocols with quality-controlled methods will definitely be needed.

AB - The current status of biochemical biomarker candidates for dementia with Lewy bodies (DLB) and synucleinopathy has been previously discussed. The majority of the studies on biochemical biomarkers were cross-sectional, retrospective, and tested with pathologically unproven subjects. α-Synuclein (A-syn) plays a pivotal role both in the development of the disease and propagation of the pathology in Parkinson’s disease (PD). Levels of total A-syn in cerebrospinal fluid (CSF) can discriminate PD from controls or tauopathies as groups. However, it is hard to diagnose an individual patient according to the level of CSF A-syn alone. The CSF total A-syn could also be useful as a surrogate biomarker for PD for monitoring the severity of the disease. CSF levels of A-syn oligomers could be a promising biomarker for the diagnosis of PD and are reported to correlate with motor and cognitive scores in PD, also suggesting their possible ability as a biomarker to monitor disease severity. With regard to the diagnosis of DLB, some studies, including two meta-analyses, demonstrated significantly lower CSF levels of total A-syn in DLB patients compared to AD patients. However, the sensitivity and specificity as well as diagnostic ability of CSF total A-syn remain to be elucidated. Whether CSF A-syn oligomers are useful or not for the diagnosis of DLB has not been examined. To study plasma levels of total and oligomeric A-syn, it is essential to eliminate the interference from heterophilic antibodies that have a significant impact on the assays of plasma A-syn, despite never being considered in any of the studies reported so far. For future studies developing biochemical biomarkers for DLB and synucleinopathy, it will be necessary to not only validate the already reported candidates and translate them to clinical practice but also to identify novel biomarkers that are more closely associated with the underlying pathophysiologies, including certain oligomers or protofibrils of A-syn that are specifically relevant to neurotoxicity and/or prion-like propagation of the diseases. To accomplish these goals, a large, prospective, and longitudinal cohort study carried out using standardized diagnostic criteria and stringent protocols with quality-controlled methods will definitely be needed.

KW - Biochemical biomarker

KW - Cerebrospinal fluid

KW - Dementia with Lewy bodies

KW - Oligomer

KW - α-Synuclein

UR - http://www.scopus.com/inward/record.url?scp=85018050547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018050547&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-55948-1_13

DO - 10.1007/978-4-431-55948-1_13

M3 - Chapter

AN - SCOPUS:85018050547

SN - 9784431559467

SP - 171

EP - 192

BT - Dementia with Lewy Bodies: Clinical and Biological Aspects

PB - Springer Japan

ER -